SCHEMBL3536751

SCHEMBL3536751

CC1CCN(c2cc(N3CCN(CCOC(=O)OC(C)(C)C)CC3)ccc2[N+](=O)[O-])CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.47
MAPT P10636 12/20 0.46
RAB9A P51151 1/20 0.46
MAPK1 P28482 1/20 0.46
GPR174 Q9BXC1 4/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
CYP2C19 P33261 2/20 0.45
CYP1A2 P05177 1/20 0.45
CTPS1 P17812 1/20 0.42
LMNA P02545 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
HPGD P15428 1/20 0.42
CYP2C9 P11712 2/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3538708 0.82 MAPT (0.60) ALDH1A1MAPTRAB9AMAPK1L3MBTL1
SCHEMBL3540449 0.82 ALDH1A1 (0.60) ALDH1A1MAPTRAB9AGPR174L3MBTL1
SCHEMBL31157984 0.82 ALDH1A1 (0.60) ALDH1A1MAPTRAB9AGPR174L3MBTL1
SCHEMBL31000430 0.78 ALDH1A1 (0.74) ALDH1A1MAPTRAB9AMAPK1L3MBTL1
SCHEMBL3541105 0.78 ALDH1A1 (0.74) ALDH1A1MAPTRAB9AMAPK1L3MBTL1
SCHEMBL27691387 0.76 MAPT (0.56) ALDH1A1MAPTRAB9AMAPK1GPR174
SCHEMBL3540276 0.74 CSF1R (0.76)
SCHEMBL14206743 0.74 DRD2 (0.41) ALDH1A1MAPTLMNAKMT2A
SCHEMBL3537199 0.73 GPR174 (0.57) ALDH1A1MAPTGPR174CYP2C19LMNA
SCHEMBL28766651 0.73 MAPT (0.55) ALDH1A1MAPTRAB9AMAPK1GPR174

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-B1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2009-07-29 EP disclosed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP disclosed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US disclosed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES ALDH1A1 4796/4885MAPT 159/4885RAB9A 4043/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.